Press Releases April 30, 2026 04:09 PM

SI-BONE To Present at BofA Securities 2026 Healthcare Conference on May 12, 2026

SI-BONE to present at BofA Securities 2026 Healthcare Conference on May 12, 2026

By Derek Hwang SIBN
SI-BONE To Present at BofA Securities 2026 Healthcare Conference on May 12, 2026
SIBN

SI-BONE, Inc., a Nasdaq-listed medical device company specializing in procedural solutions for compromised bone, announced its participation in the 2026 BofA Securities Healthcare Conference with a scheduled fireside chat. The event offers management a platform to discuss company developments and engage with investors.

Key Points

  • SI-BONE is a global leader in developing procedural solutions targeting spinopelvic anatomy and compromised bone conditions.
  • The company has supported over 140,000 procedures since 2009 with strong clinical evidence supporting its technologies.
  • The upcoming presentation at the BofA Securities Healthcare Conference provides an opportunity to showcase company strategy and innovations to investors.

SANTA CLARA, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today announced that the company will be participating in the upcoming 2026 BofA Securities Healthcare Conference in Las Vegas, NV. Management will be hosting a fireside chat on Tuesday, May 12, 2026, at 8:00 a.m. Pacific Time/11:00 a.m. Eastern Time.

Investors interested in listening to the conference call may do so by registering at this link: https://bofa.veracast.com/webcasts/bofa/healthcare2026/f3F578.cfm. Live audio of the webcast will be available on the “Investors” section of the company’s website at: www.si-bone.com. The webcast will be archived and available for replay for at least 90 days after the event.

About SI-BONE, Inc.

SI-BONE (NASDAQ: SIBN) is a global leader in developing procedural solutions to address clinical challenges associated with compromised bone. With expertise in biomechanical design and anatomy specific innovation, SI-BONE has built a technology platform with market-leading applications centered on the spinopelvic anatomy. SI-BONE continues to leverage the deep experience in addressing the challenges of low-density bone in the sacrum to develop unique technologies that are targeting new clinical adjacencies to help improve outcomes for patients with compromised bone. Since 2009, SI-BONE has supported physicians in performing a total of over 140,000 procedures. A unique body of clinical evidence supports the use of SI-BONE's technologies, including four randomized controlled trials and over 180 peer reviewed publications.

For additional information on the company or the products, including risks and benefits, please visit www.si-bone.com.

SI-BONE® is a registered trademark of SI-BONE, Inc. ©2026 SI-BONE, Inc. All Rights Reserved.

Investor Contact

Saqib Iqbal
VP, FP&A and Investor Relations
[email protected]


Risks

  • Market adoption of SI-BONE's proprietary technologies depends on continued clinical validation and physician acceptance, which can fluctuate.
  • Competition in the orthopedic and medical device sectors may impact future growth and technology adoption.
  • Regulatory and reimbursement environments can influence the company’s ability to market and sell its products effectively.

More from Press Releases

Figure Technology Solutions Reports April 2026 Operating Data May 4, 2026 Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) May 4, 2026 TWFG Insurance Acquires APIA Inc., Expanding Specialty MGA Capabilities and Supporting Long-Term Growth May 4, 2026 Pennant Announces First Quarter 2026 Earnings Release and Call May 4, 2026 Magna Announces 2026 Annual Meeting Results May 4, 2026